Literature DB >> 7648491

Ototoxicity associated with intravenous bisphosphonate administration.

I R Reid1, D A Mills, D J Wattie.   

Abstract

The development of ototoxicity in association with intravenous pamidronate treatment of Paget's disease is described. The patient developed hearing loss, vertigo, and tinnitus which were exacerbated by subsequent infusions. This potentially serious drug side-effect does not appear to have been reported previously in patients with Paget's disease.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7648491     DOI： 10.1007/bf00298594

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN： 0171-967X            Impact factor:   4.333


  6 in total

Review 1.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

2.  Urinary excretion of aminohydroxypropylidene bisphosphonate in cancer patients after single intravenous infusions.

Authors:  E Redalieu; J M Coleman; K Chan; J Seaman; P H Degen; G Flesch; A Brox; G Batiste
Journal:  J Pharm Sci       Date:  1993-06       Impact factor: 3.534

3.  Clearance and tissue uptake following 4-hour and 24-hour infusions of pamidronate in rats.

Authors:  M Pongchaidecha; P T Daley-Yates
Journal:  Drug Metab Dispos       Date:  1993 Jan-Feb       Impact factor: 3.922

4.  The detrimental effect of aminohydroxypropylidene bisphosphonate (APD) in otospongiosis.

Authors:  L J Boumans; R M Poublon
Journal:  Eur Arch Otorhinolaryngol       Date:  1991       Impact factor: 2.503

5.  Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis.

Authors:  I R Reid; D J Wattie; M C Evans; G D Gamble; J P Stapleton; J Cornish
Journal:  J Clin Endocrinol Metab       Date:  1994-12       Impact factor: 5.958

6.  Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause.

Authors:  D Thiébaud; P Burckhardt; J Melchior; P Eckert; A F Jacquet; P Schnyder; C Gobelet
Journal:  Osteoporos Int       Date:  1994-03       Impact factor: 4.507
  6 in total
  6 in total

Review 1.  Adverse effects of bisphosphonates. A comparative review.

Authors:  S Adami; N Zamberlan
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

2.  Further hearing loss during osteoporosis treatment with etidronate.

Authors:  S Yaşil; A Cömlekçi; A Güneri
Journal:  Postgrad Med J       Date:  1998-06       Impact factor: 2.401

3.  Tolerability of intravenous pamidronate for the treatment of osteoporosis and other metabolic osteopathies: A retrospective analysis.

Authors:  Marcelo Sarli; Rodolfo Spivacow; Viviana Pedroarias; Emilio J A Roldán; José R Zanchetta
Journal:  Curr Ther Res Clin Exp       Date:  2007-01

4.  Third-generation bisphosphonates for treatment of sensorineural hearing loss in otosclerosis.

Authors:  Alicia M Quesnel; Margaret Seton; Saumil N Merchant; Christopher Halpin; Michael J McKenna
Journal:  Otol Neurotol       Date:  2012-10       Impact factor: 2.311

Review 5.  Bisphosphonates in bone diseases.

Authors:  R W Sparidans; I M Twiss; S Talbot
Journal:  Pharm World Sci       Date:  1998-10

Review 6.  Drug-Drug Interactions in Vestibular Diseases, Clinical Problems, and Medico-Legal Implications.

Authors:  Giulio Di Mizio; Gianmarco Marcianò; Caterina Palleria; Lucia Muraca; Vincenzo Rania; Roberta Roberti; Giuseppe Spaziano; Amalia Piscopo; Valeria Ciconte; Nunzio Di Nunno; Massimiliano Esposito; Pasquale Viola; Davide Pisani; Giovambattista De Sarro; Milena Raffi; Alessandro Piras; Giuseppe Chiarella; Luca Gallelli
Journal:  Int J Environ Res Public Health       Date:  2021-12-08       Impact factor: 3.390
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.